Risk classification for overall survival by the neutrophil–lymphocyte ratio and the number of metastatic sites in patients treated with pembrolizumab—a multicenter collaborative study in Japan
Dive into the research topics of 'Risk classification for overall survival by the neutrophil–lymphocyte ratio and the number of metastatic sites in patients treated with pembrolizumab—a multicenter collaborative study in Japan'. Together they form a unique fingerprint.